Conquering Diseases

Extension of Investigational Drug for Participants of CENTAUR Study


This is an extension of a study of the safety and effectiveness of an investigational drug to treat Amyotrophic Lateral Sclerosis (ALS)


This study is to give ALS patients who participated in the CENTAUR study longer-term access to the investigational drug AMX0035

What we're hoping for

We will evaluate the safety and effectiveness of the investgational drug AMX0035 for treatment of ALS

Additional Information Identifier: NCT03127514

 Principal Investigator

Margaret  Owegi, DO

UMass Memorial Health Care

 Study Contact

Catherine  Douthwright



UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655